Skip to main content
. 2023 Dec 20;3(12):2585–2595. doi: 10.1158/2767-9764.CRC-23-0394

FIGURE 2.

FIGURE 2

Activation of peripheral blood CD8+ T cells in immunologic R but not in immunologic NR during p53MVA/pembrolizumab treatment. The immune response of p53-specific CD8+ T cells from PBMC, as determined by flow cytometric analysis, is compiled for 18/28 evaluable in correlative studies patients (R: n = 6; NR: n = 12; A), as well as is shown for 1 representative R patient (B) and 1 NR patient (C). Frequencies of activated CD8+ TEM and TEF cells are shown in D and E, respectively. R patients normalized CA-125 serum levels to <30 U/mL by week 6 of treatment (F and G) in contrast to NR patients who exhibited gradual increase of CA-125 (F and H). *, P < 0.05, unpaired two-tailed t test except for two-tailed paired t test in F comparing NR Pre versus NR Wk+6 and R Pre versus R Wk+6 (whiskers indicate 5–95 percentiles).